CLL Society is hosting an X Spaces event on 12/17 at 3PM ET. Following the #ASH2024 Annual Meeting, we'll be discussing breaking research developments in #CLL with @briankoffman, @chadinabhan, @ASkarbnik, @AdamKittai, @DebbieMStephens, @NitinJainMD. bit.ly/3ZqHapFView quoted post on X
Latest posts 5
@SWOG S1925 is still enrolling patients diagnosed with #CLL within the last 18 months with high risk disease. Can time limited early venetoclax + obinutuzumab prolong survival in these patients? We aim to find out. Please consider screening and enrolling your patients!
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: Phase III CLL12 Trial shows watch and wait still remains the standard. @JCO_ASCO The @SWOG S1925 trial is asking a similar question with venetoclax. @DebbieMStephens ascopubs.org/doi/full/10.12…View quoted post on X
Congrats to all, but special shout out to @ChrisJensenMD for his work to address fatigue for patients with #CLL. @UNC_Lineberger @UNC_Health_Care
Congratulations to our 2024 research grant awardees advancing the field of #CLL!View quoted post on X
Jennifer Brown, MD, PhD from @DanaFarber
@PrajishIyer from @cityofhope
@ChrisJensenMD from @UNC
John Byrd, MD from @uofcincy
PR: prn.to/3WxSZdc
2024 awardees: bit.ly/3oXE2CX
Checking out the sites in @cityoftoronto before the #CCTG meeting.